Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04544462 · ClinicalTrials.gov registry record
ANXA5 M2 Haplotyping in IVF Patients and Embryos
A clinical trial of Infertility and Pregnancy Complications, sponsored by Genomic Prediction.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04544462: Active study of Infertility and Pregnancy Complications, sponsored by Genomic Prediction.
NCT04544462 is a study of Infertility and Pregnancy Complications that is active but no longer recruiting, run by Genomic Prediction. The registered enrollment target is 500 participants, below the 7,583-participant average among 74 other Infertility trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04544462, a study of Infertility and Pregnancy Complications, is active but no longer recruiting, sponsored by Genomic Prediction.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to characterize the association between history of pregnancy complications and M2 carrier status in IVF patients and the utility of M2 haplotype preimplantation genetic testing (PGT) in embryos produced by carrier couples. Participants in this study will be screened for the M2 variant. History of pregnancy complications and miscarriages will be studied in order to determine potential associations with M2 carrier-ship.
Primary Outcome
Frequency of carriers of the M2 haplotype attending an IVF center for infertility treatment.
Conditions Studied
Interventions
- OTHER M2 Test
Study Locations (1)
New Jersey
- Genomic Prediction Clinical Laboratory - North Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2026-12 |
What the registry record for NCT04544462 still lists
NCT04544462 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 7,583-participant average among 74 other Infertility trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Infertility appearing as the primary indexed condition, and to 1 intervention - of which M2 Test is the first listed.
NCT04544462 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04544462 about?
NCT04544462 is a clinical study titled "ANXA5 M2 Haplotyping in IVF Patients and Embryos". This study aims to characterize the association between history of pregnancy complications and M2 carrier status in IVF patients and the utility of M2 haplotype preimplantation genetic testing (PGT) in embryos produced by carrier couples. Participants in this study will be screened for the M2 varian...
What is the current status of trial NCT04544462?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2020-02-10. Estimated completion is 2026-12.
What conditions does trial NCT04544462 study?
This clinical trial studies the following conditions: Infertility, Pregnancy Complications, Miscarriage, Recurrent.
What interventions are being tested in trial NCT04544462?
The interventions under investigation include: M2 Test (OTHER).
Who is sponsoring clinical trial NCT04544462?
This trial is sponsored by Genomic Prediction, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04544462 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04544462's enrollment target sits among peer trials
500 24th of 74 higher than 50 of 74 other Infertility trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infertility trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
-
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
RECRUITING · Phase 1
-
Non-Euploid Embryo Transfer (NEET) Registry
RECRUITING
-
Validating Incubators in the Lab: Optimizing Culture and Investigating blasTulation Yield
RECRUITING · NA
-
Apple Women's Health Study
RECRUITING
-
Discarded Materials Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI